Guardian Capital LP decreased its position in shares of Stryker Corporation (NYSE:SYK) by 14.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,643 shares of the medical technology company’s stock after selling 20,174 shares during the quarter. Guardian Capital LP’s holdings in Stryker Corporation were worth $16,604,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Stryker Corporation by 2.8% in the second quarter. Vanguard Group Inc. now owns 24,078,709 shares of the medical technology company’s stock worth $3,341,643,000 after purchasing an additional 657,656 shares during the last quarter. BlackRock Inc. boosted its holdings in Stryker Corporation by 5.2% in the second quarter. BlackRock Inc. now owns 23,115,853 shares of the medical technology company’s stock worth $3,208,017,000 after purchasing an additional 1,139,082 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Stryker Corporation by 0.5% in the first quarter. Wellington Management Group LLP now owns 4,569,118 shares of the medical technology company’s stock worth $601,525,000 after purchasing an additional 24,139 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Stryker Corporation by 6.3% in the first quarter. Geode Capital Management LLC now owns 2,786,406 shares of the medical technology company’s stock worth $366,255,000 after purchasing an additional 166,133 shares during the last quarter. Finally, Jensen Investment Management Inc. boosted its holdings in Stryker Corporation by 9.9% in the second quarter. Jensen Investment Management Inc. now owns 2,220,791 shares of the medical technology company’s stock worth $308,201,000 after purchasing an additional 200,192 shares during the last quarter. Hedge funds and other institutional investors own 74.10% of the company’s stock.

Shares of Stryker Corporation (NYSE:SYK) opened at 148.79 on Wednesday. Stryker Corporation has a one year low of $106.48 and a one year high of $149.23. The company has a market capitalization of $55.66 billion, a P/E ratio of 33.21 and a beta of 0.80. The firm has a 50-day moving average of $143.05 and a 200-day moving average of $140.60.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.39 earnings per share. Analysts forecast that Stryker Corporation will post $6.45 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s dividend payout ratio is presently 37.95%.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/stryker-corporation-syk-stake-lowered-by-guardian-capital-lp/1638670.html.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total value of $731,800.00. Following the completion of the sale, the insider now directly owns 88,207 shares in the company, valued at $12,909,976.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The disclosure for this sale can be found here. Corporate insiders own 7.40% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Cowen and Company set a $160.00 target price on shares of Stryker Corporation and gave the stock a “buy” rating in a report on Friday, October 6th. Zacks Investment Research cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. BidaskClub upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Royal Bank Of Canada raised their target price on shares of Stryker Corporation from $140.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Stryker Corporation and gave the stock a “hold” rating in a report on Friday, July 28th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $146.78.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.